# Fosrenol Post-marketing Surveillance for Hemodialysis in Japan

> **NCT01419327** · — · COMPLETED · sponsor: **Bayer** · enrollment: 3267 (actual)

## Conditions studied

- Hyperphosphatemia

## Interventions

- **DRUG:** Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet

## Key facts

- **NCT ID:** NCT01419327
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03-23
- **Primary completion:** 2019-01-30
- **Final completion:** 2019-05-28
- **Target enrollment:** 3267 (ACTUAL)
- **Last updated:** 2020-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01419327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01419327, "Fosrenol Post-marketing Surveillance for Hemodialysis in Japan". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01419327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*